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Abstract
Background: Hormone receptor-positive/HER2−negative (HR+/HER2−) breast cancer is 
associated with low levels of stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1, and 
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demonstrates poor responses to checkpoint inhibitor therapy. Evaluating the effect of standard 
chemotherapy on the immune microenvironment may suggest new opportunities for 
immunotherapy-based approaches to treating HR+/HER2− breast tumors.
Methods: HR+/HER2− breast tumors were analyzed before and after neoadjuvant chemotherapy. 
sTIL were assessed histologically; CD8+ cells, CD68+ cells, and PD-L1 staining were assessed 
immunohistochemically; whole transcriptome sequencing and panel RNA expression analysis 
(NanoString) were performed.
Results: 96 patients were analyzed from two cohorts (N=55 Dana-Farber cohort; N=41 MD 
Anderson cohort). sTIL, CD8, and PD-L1 on tumor cells were higher in tumors with basal PAM50 
intrinsic subtype. Higher levels of tissue-based lymphocyte (sTIL, CD8, PD-L1) and macrophage 
(CD68) markers as well as gene expression markers of lymphocyte or macrophage phenotypes 
(NanoString or CIBERSORT) correlated with favorable response to neoadjuvant chemotherapy, 
but not with improved distant metastasis-free survival in these cohorts or a large gene expression 
dataset (N=302). In paired pre-/post-chemotherapy samples, sTIL and CD8+ cells were 
significantly decreased post-treatment while expression analyses (NanoString) demonstrated 
significant increase of multiple myeloid signatures. Single gene expression implicated increased 
expression of immunosuppressive (M2-like) macrophage-specific genes post-chemotherapy.
Conclusions: The immune microenvironment of HR+/HER2−tumors differs according to tumor 
biology. This cohort of paired pre-/post-chemotherapy samples suggests a critical role for 
immunosuppressive macrophage expansion in residual disease. The role of macrophages in 
chemo-resistance should be explored and further evaluation of macrophage-targeting therapy is 
warranted.
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Introduction
Hormone receptor-positive/HER2−negative (HR+/HER2−) tumors make up over two-thirds 
of all breast cancer(1). Examination of the breast cancer tumor microenvironment (TME) 
suggests that HR+ breast tumors may be more immunologically “cold” than their triple-
negative and HER2−positive counterparts. These observations are primarily based on 
assessment of tumor-infiltrating lymphocytes (TIL) and expression of the T cell checkpoint 
protein programmed death-ligand 1 (PD-L1; or its receptor, PD-1) in treatment-naïve 
tumors. TIL infiltration is lower in ER-positive as compared to ER-negative tumors(2), and 
there is an inverse correlation between estrogen receptor (ER) positivity and PD-1/PD-L1 
expression(3–5). Chemotherapy can elicit anti-tumor immune responses through a variety of 
mechanisms, including triggering antigen release from dying tumor cells, stimulation of 
immune effector cells, and inhibition of immune regulatory cells(6). The 
immunomodulatory effects of chemotherapy on HR+/HER2− breast tumors specifically 
have not been widely explored.
Immune checkpoint inhibitor therapy has revolutionized the treatment landscape and 
improved prognosis for many malignancies. To date, however, responses to immune 
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checkpoint inhibitor monotherapy have been marginal in HR+ breast cancer. In patients with 
refractory HR+/HER2− metastatic breast cancer, the anti-PD-L1 antibody avelumab led to 
an overall response rate of 2.8% (among patients unselected for PD-L1 status), and the anti-
PD-1 antibody pembrolizumab led to an overall response rate of 12% (among patients with 
PD-L1-positive tumors)(7,8). Given the prevalence of HR+/HER2− breast cancer, 
identifying even a small subset of immunologically “hot” HR+/HER2− tumors could be 
clinically significant and allow identification of patients likely to benefit from 
immunotherapy. While most analysis of the TME in breast cancer to date has focused on T 
lymphocytes and T cell checkpoints, evidence from both preclinical models and clinical 
specimens suggests that macrophages and their associated regulatory pathways play a 
particularly important role in pathogenesis and treatment response of HR+ breast tumors(9–
11). A broader assessment of the TME in HR+/HER2− breast tumors is needed.
The goal of this study was to examine both tissue-based and RNA-based immune 
biomarkers in patients with HR+/HER2− non-metastatic breast cancer treated with 
chemotherapy. By incorporating and extending analyses beyond investigation of 
lymphocyte-mediated immune responses, with a particular focus on macrophages, we 
sought to identify candidate biomarkers of response to therapy, to gain insights into immune-
related biological processes that may be harnessed for therapeutic potential, and to analyze 
the heterogeneity that exists in the HR+ TME. Two cohorts of patients treated with standard 
neoadjuvant chemotherapy (plus the anti-vascular endothelial growth factor (VEGF) 
antibody bevacizumab in one cohort), were used to examine how the TME changes 
following treatment. Results from a variety of methods used to assess the TME (including 
histology, protein expression, and gene expression), were integrated to capture multiple 




The first cohort, from Dana-Farber Cancer Institute (DFCI), consisted of patients enrolled on 
a prospective clinical trial (DFCI #07–130); see REMARK diagram (Figure S1). Patients 
enrolled on trial with HR+/HER2− breast cancer had node-positive or high-risk node-
negative tumors without distant metastases. Details of trial design, eligibility, treatment 
regimen, and clinical results have been reported previously(12). Briefly, patients received a 
single dose of bevacizumab followed by dose-dense adriamycin/cyclophosphamide (ddAC) 
then dose-dense paclitaxel/bevacizumab, all delivered in the neoadjuvant setting. Patients 
included in this post-hoc analysis had HR+ (ER ≥1% or progesterone receptor (PR) ≥1%) 
and HER2− breast cancer, received at least one dose of on-trial therapy, and had at least one 
tissue specimen available for evaluation. Pathologic complete response (pCR) and residual 
cancer burden (RCB)(13) at surgery were determined by central pathology review. Long-
term disease-free survival (DFS) and overall survival (OS) outcomes were determined by 
retrospective chart review. DFS events were defined as local/regional invasive breast cancer 
recurrence, contralateral invasive breast cancer, distant recurrence, or death from any cause. 
The second cohort, from the University of Texas MD Anderson Cancer Center, consisted of 
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patients with HR+ (ER ≥1% or progesterone receptor (PR) ≥1%) and HER2− breast cancer 
who received neoadjuvant chemotherapy with adriamycin, cyclophosphamide, and paclitaxel 
(T-AC) without bevacizumab, and had tumor tissue available for analysis from both pre-
treatment and post-treatment (surgical) timepoints. All analyses were approved by the 
institutional review boards of DFCI or MD Anderson Cancer Center. Research was 
conducted in accordance with the US Common Rule, and written informed consent was 
obtained from each subject.
Tissue-based biomarker assessment
Stromal TILs were scored on an hematoxylin and esosin (H&E) stained slide by a breast 
pathologist according to international consensus guidelines(14). Immunohistochemical 
(IHC) staining of formalin-fixed paraffin-embedded (FFPE) slides was performed using 
monoclonal antibodies against CD8 (DAKO M7103), CD68 (DAKO M0876), and PD-L1 
(clone 9A11, Cell Signaling). Scoring for PD-L1 was measured by percentage of cells 
stained in tumor and stromal tissue compartments. For image analysis, three to five 
representative pictures were taken for each case at 200× magnification. The images were 
analyzed using Inform2.3 Image Analysis Software (Mantra Software/PerkinElmer). 
Positive staining was assessed quantitatively, and thresholds used to bin data were selected 
based on individual biomarker distribution and existing standards.
NanoString immune gene expression panel analysis
RNA was isolated from areas of invasive tumor on FFPE slides. Two hundred ng of RNA per 
sample was loaded and run on the HuV1_CancerImmu_v1_1 Nanostring for analysis of the 
NanoString PanCancer Immune Profiling Panel (PCI; DFCI cohort) or the PanCancer IO 
360 Profiling Panel (IO360; MD Anderson cohort). Raw gene counts for both cohorts were 
log2 transformed and normalized to the geometric mean of 10 housekeeper genes common 
between panels. For gene signatures, 20 NanoString signatures previously found to be highly 
correlated between PCI and IO360 panels were analyzed. A modified version of the Tumor 
Inflammation Signature (TIS; using 16 of 18 genes in the published signature) was used for 
samples in the PCI/DFCI cohort. Additional signatures were computed after normalization 
to 20 housekeeping genes and removal of samples with low housekeeper expression. 
Signature scores range from approximately 0 to 10, with an average value of 5 in pancancer 
tumor samples from The Cancer Genome Atlas(15).
DFCI cohort whole transcriptome sequencing and analysis
Gene expression profiles for the clinical trial samples were generated by mRNA sequencing 
using the Illumina TruSeq Kit to create libraries for paired-end sequencing on an Illumina 
HiSeq 2000. Data was aligned and genes quantified as previously described(16), as upper 
quartile normalized RSEM abundance estimates that were log2 transformed. Gene 
expression samples and patients were also derived from a large previously published meta-
analysis of patients with HR+/HER2− breast cancer treated with neoadjuvant 
chemotherapy(17). The Parker et al. predictor was used for subtype categorizations using a 
nearest centroid procedure which returned calls as a five-level classifier (Basal-like, Luminal 
A, Luminal B, HER2−enriched, and Normal-like)(18). Proportion of infiltrating immune cell 
subsets was calculated using the CIBERSORT algorithm(19).
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Association between biomarker assessments, gene expression profiles and patient 
characteristics are made under a general linear model with Student t-tests, ANOVA, and 
Pearson correlation coefficients (r) as indicated in the text. Changes in quantitative 
biomarkers from pre- to post-neoadjuvant treatment were made using Wilcoxon signed rank 
test. Kaplan-Meier plots were generated using ‘packHV’ package(20). Differences in the 
survival function were calculated by log rank test. A nominal p < 0.05 was used to declare 
statistical significance. For each gene expression analysis, the Benjamini-Hochberg step-up 
procedure was used to control the false discovery rate (FDR)(21). Statistical analyses were 
performed using STATA version 14.2 and R version 3.4.1.
Results
Patient characteristics
96 patients with HR+/HER2− breast tumors were analyzed from two separate cohorts, one 
from DFCI (N=55) and one from MD Anderson (N=41). Characteristics of patients from 
both cohorts are summarized in Table 1. All patients in both cohorts had tumors positive for 
ER and/or PR expression, and the large majority had either grade 2 (54–55%) or 3 (29–40%) 
tumors. At the time of surgery following pre-operative therapy, most patients (82% in DFCI 
cohort; 93% in the MD Anderson cohort) had RCB(13) class of II or III, and only 4 patients 
from the DFCI cohort had pCR (RCB score 0). Of note, since only patients with pre- and 
post-chemotherapy tumor tissue available were selected for the MD Anderson cohort, there 
were no patients with pCR in this cohort.
Immune biomarkers and tumor intrinsic subtype
Stromal TIL, PD-L1 protein expression on tumor and stromal cells, CD8, and CD68 protein 
expression were measured in treatment-naïve breast biopsy specimens from all patients in 
the DFCI cohort; distribution of each biomarker is shown in Table S1. The majority of 
patients (82%) had <10% sTIL infiltration; no patients had lymphocyte-predominant breast 
cancer (≥60% TIL)(14). The large majority (78%) of patients were negative (defined as 
<1%) for tPD-L1, and an even greater percentage (88%) had negative PD-L1 expression on 
stromal cells (sPD-L1), though remaining patients did demonstrate expression of tumor or 
stromal PD-L1 at a level (≥1%) shown to be clinically significant in breast cancer(22).
Available primary tumors (N=38 patients) from the DFCI cohort underwent RNA 
sequencing and tumor intrinsic subtype was classified by PAM50 gene signature (Table 1). 
The majority (63%) were classified as luminal A. Of note, all 6 tumors determined to be 
basal subtype by PAM50 had ER expression ≤15% (≤10% in 5 of 6 tumors), and PR 
expression ≤10%. There was significant variation between luminal A, luminal B, and basal 
tumors in terms of sTIL, CD8, and tPD-L1 (ANOVA p=0.03, p=0.0006, p=0.02, 
respectively) but not CD68 (ANOVA p=0.18; Figure 1). For all biomarkers except CD68, 
median levels were highest in basal tumors. In addition, the highest values observed for each 
biomarker were clustered in the basal subtype. However, luminal A and luminal B tumors 
also displayed a range of values (including some higher values) for all biomarkers, with the 
exception of tPD-L1 in luminal A tumors, which was universally low (only 2 patients had 
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expression ≥1%; maximum 1.2%). The modified TIS (a gene expression profile denoting 
interferon-gamma-related signaling that has been shown to predict clinical response to 
immune checkpoint blockade(15)) also differed significantly across tumor intrinsic subtypes 
(ANOVA p=0.0016; Figure S2). Basal tumors had the highest median TIS (9.68). However, 
luminal A tumors spanned a range of TIS values, with 2/14 samples scoring ≥9, in the same 
range as basal tumors.
Immune biomarkers, response to neoadjuvant chemotherapy, and distant metastasis-free 
survival
In both unadjusted models and models adjusted for tumor size and grade, all tissue-based 
immune-related biomarkers assessed in the DFCI cohort (sTIL, CD8, CD68, tPD-L1, sPD-
L1) were significantly associated with more favorable RCB score (Table S1). Of the 4 
patients with pCR in the DFCI cohort, all had either the highest or among the highest values 
in the cohort for multiple tissue-based immune biomarkers; they also had basal or luminal B 
intrinsic subtype (Table S2). All 3 patients with sPD-L1 expression ≥5% at baseline 
experienced a pCR. Correlations between biomarkers and pCR status were not assessed 
given the low number of patients with pCR. There was no significant association between 
RCB and pre-to-post-treatment change in sTIL, CD8, CD68, tPD-L1, or sPD-L1.
Since CD68 can stain some non-macrophage cell types(23), and since macrophages can take 
on a variety of different biological roles which CD68 staining does not distinguish, we used 
RNA expression data to investigate the relationship between macrophages and response to 
neoadjuvant chemotherapy. Higher expression of the Nanostring PanCancer Immune Panel 
macrophage signature (PCI.Macrophage) was significantly correlated with more favorable 
response to neoadjuvant chemotherapy (as assessed by RCB score) (Figure 2A). The 
PCI.Macrophage signature was positively correlated with the proportion of macrophages 
identified by the M1 macrophage signature (pro-inflammatory/anti-tumor) as measured by 
expression-based inferred immune subset proportion, determined via CIBERSORT(19) 
(Pearson’s r=0.57). Using gene expression data from a large cohort of patients with HR+/
HER2− breast tumors who received neoadjuvant chemotherapy, collected for a previously 
published meta-analysis (17), we similarly found that macrophages identified by the 
CIBERSORT M1 signature correlated with more favorable RCB response to chemotherapy 
(N=302 patients with RCB status; Figure 2B). Taken together, these data suggest that anti-
tumor M1-like macrophages behave like lymphocyte-related immune markers (sTIL, CD8, 
and PD-L1) with respect to predicting response to neoadjuvant chemotherapy. By contrast, a 
signature representing immune suppressive myeloid-derived suppressor cells (MDSCs)(24) 
showed a non-statistically significant visual trend in the opposite direction, with lower 
MDSC signature values corresponding to more favorable RCB response to chemotherapy 
(ANOVA p=0.17; N=302 pts with RCB status and adequate signature gene representation; 
Figure 2C).
Given the positive correlation between both lymphocyte-related and macrophage-related 
immune markers and favorable response to neoadjuvant chemotherapy, we assessed the 
correlation between immune markers and long-term breast cancer outcomes. In the DFCI 
cohort, there were 14 DFS events (12 distant recurrences, 1 loco-regional recurrence, 1 non-
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breast cancer death) and median DFS was 9.7 years (median OS not reached; median 
follow-up 7.9 years). There were no DFS events among the patients with pCR. There was no 
significant correlation of DFS with any tissue-based biomarker measured before or after 
treatment, in both adjusted and unadjusted models, with Cox regression hazard ratios near 1 
in all cases (data not shown). Since this analysis was underpowered due to the small sample 
size of the cohort, we calculated the correlation between M1-like or M2-like macrophages, 
MDSCs, or CD8 lymphocytes (by CIBERSORT) and distant metastasis-free survival 
(DMFS) in patients from the large meta-analysis cohort (N=272 with outcome data; median 
follow-up 3.0 years). There was no significant correlation between macrophages identified 
by either the M1 or M2 CIBERSORT signatures, MDSC gene signature, or CIBERSORT 
CD8 lymphocyte proportion (stratified by above/below median) with DMFS (Figure 2D–2E; 
data not shown for M2 macrophages and MDSC signature).
Changes in the immune microenvironment after neoadjuvant chemotherapy
In the DFCI cohort, tissue-based immune biomarkers were scored both before and after 
neoadjuvant treatment with ddAC-T plus bevacizumab. sTIL and CD8+ T cells both 
decreased significantly post-treatment in paired analyses (Wilcoxon signed rank p=0.037 
and p=0.002, respectively); there was a trend toward a decrease in tPD-L1 expression post-
treatment (Wilcoxon signed rank p=0.081), and there was no significant change in the 
number of CD68+ cells (Figure 3A–3D). Histologic images from a representative patient 
with pre-to-post-treatment decrease in sTIL, CD8, and CD68 are shown (Figure 3E).
For a more complete assessment of changes in the TME following chemotherapy, we used 
NanoString gene expression analysis to compare pre- and post-chemotherapy immunologic 
features in the separate patient cohorts (DFCI N=22 patients with paired samples, treated 
with ddAC-T plus bevacizumab; and MD Anderson N=41 patients with paired samples, 
treated with T-AC without bevacizumab). Changes in NanoString gene expression signatures 
pre-to-post-chemotherapy in paired samples were examined (Figure 4A). Upregulation of 
lymphoid, T cell, or CD8 T cell signatures was not observed, consistent with tissue-based 
biomarker data, though a decrease in T regulatory cells was seen. There were significant 
increases in macrophages, dendritic cells, and a myeloid inflammation signature (which 
captures functional myeloid markers) post-chemotherapy in both the DFCI and MD 
Anderson cohorts (Figure 4B).
Expression level changes in individual genes pre-to-post-chemotherapy were also examined. 
Figure 5A shows genes whose expression changed significantly post-chemotherapy (by false 
discovery rate (FDR) p-value <0.05) in both the DFCI and MD Anderson cohorts. The most 
significantly upregulated gene in post-treatment samples was EGR1 (early growth response 
1), a master regulator transcription factor with highly diverse biological roles(25). The most 
significantly downregulated gene in both cohorts was BIRC5, which is a component of the 
PAM50 proliferation signature and highly correlated to tissue Ki-67 staining(26) and 
mammary epithelial proliferation in 3D culture(17); reduced proliferation in residual tumor 
cells is a known effect of chemotherapy(26). Other upregulated genes in both cohorts 
included MRC1 and CCL14, both genes that are important for and specific to macrophage 
functions. Gene expression changes were highly concordant between the two cohorts; results 
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for each cohort individually are shown in Figure S3. Because signature analysis suggested a 
significant increase in macrophages post-chemotherapy, but macrophages are a 
heterogeneous group of immune cells with many different biological roles, we used 
individual gene expression data to infer changes in M1-like (pro-inflammatory/anti-tumor) 
versus M2-like (immunosuppressive/pro-tumor) macrophages (Figure 5B–C). We hand 
curated a list of genes associated with M1-like versus M2-like macrophage phenotypes 
based on comprehensive literature review (Table S3). Only 2/9 genes associated with M1-
like macrophage phenotype increased significantly post-chemotherapy in both DFCI and 
MD Anderson cohorts, while in contrast, 8/13 genes associated with a M2-like macrophage 
phenotype increased significantly post-chemotherapy in both cohorts. Overall, M2-like 
macrophage-associated genes were upregulated more frequently and displayed higher fold-
change post-chemotherapy than M1-like-associated genes.
Discussion
In this study, we used histology, protein expression, and gene expression analyses to 
examine the TME of HR+/HER2− breast cancer patients treated with neoadjuvant 
chemotherapy. Immunohistochemical profiles of HR+/HER2− tumors at baseline 
demonstrate significant variation by intrinsic subtype. In detailed pre-/post-neoadjuvant 
chemotherapy analyses, we demonstrated reduction in sTIL and CD8+ T cells with 
concurrent upregulation of macrophage-related gene expression—specifically the M2-like, 
pro-tumor macrophage phenotype.
sTIL, CD8, tPD-L1, and immune gene expression signatures varied significantly between 
HR+ tumors with different intrinsic subtypes, with the highest levels clustering within the 
basal-like subtype (where ER expression was low, and PR expression was often negative). 
This suggests that with respect to the immune microenvironment and thus, potentially, 
responsiveness to immunotherapy, tumors with low (≤10%) ER and PR expression may be 
better grouped with triple-negative breast cancer than with more strongly ER/PR-positive 
tumors. This assertion has potential implications for future clinical trial design, but given 
small numbers reported here, requires further exploration. Differences in the TME between 
luminal A and luminal B tumors were not substantial in our dataset (with the exception of 
tPD-L1 expression which was universally low in luminal A tumors). Interestingly, by both 
immunohistochemical- and expression-based metrics, a subset of luminal A tumors appeared 
to have elevated immune activity, including high TIS scores (a marker of responsiveness to 
immune checkpoint blockade)(15). This implies that luminal A tumors should be 
investigated in greater depth to understand the biological underpinnings of the full spectrum 
of TMEs. Despite infrequent HR+ tumors with elevated immune activity, most tumors 
reflect a relatively immune suppressed microenvironment. The role of immunosuppressive 
cells in the induction or maintenance of this immune suppressed state warrants further 
investigation.
Our results also add to the literature regarding the utility of tissue- and RNA-based immune 
biomarkers for predicting short-term response to chemotherapy versus long-term outcome 
from breast cancer. Importantly, higher levels of all tissue biomarkers (sTIL, CD8, CD68, 
tPD-L1, and sPD-L1) and a macrophage gene expression signature assessed in pre-treatment 
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specimens in the DFCI cohort had a significant positive correlation with favorable 
pathologic response to preoperative therapy, yet none of the tissue biomarkers measured 
either pre- or post-neoadjuvant therapy had a significant correlation with DFS. Similar 
analysis of gene expression-based immune biomarkers from a significantly larger cohort of 
patients with HR+/HER2− breast cancer treated with neoadjuvant chemotherapy 
demonstrated the same pattern: higher anti-tumor immune activity at baseline was associated 
with favorable pathologic response to chemotherapy, but had no effect on distant metastasis-
free survival. By contrast, expression of an immune-suppressive MDSC signature showed a 
non-statistically significant correlation with less favorable response to preoperative 
chemotherapy, still with no relationship to distant metastasis-free survival. These findings 
corroborate and build on prior work in HR+/HER2− breast cancer. More sTIL have been 
shown to predict pCR to neoadjuvant chemotherapy in all three breast cancer subtypes(27–
29), but in HR+/HER2− disease, this has not translated into improved long-term 
outcomes(29).
The value of immune biomarkers as predictive in the short-term but not prognostic in the 
long-term in HR+/HER2− breast cancer, in contrast to HER2+ and triple-negative tumors, is 
intriguing. The contribution of estrogen-driven oncogenesis to tumor growth may ultimately 
be the primary determinant of long-term outcomes in HR+/HER2− breast cancer. One 
possibility is that the HR+/HER2− tumors with higher immune biomarkers at baseline may 
be less estrogen-driven, explaining both their better response to neoadjuvant chemotherapy 
and less favorable long-term outcomes(30). Also, higher expression of an inflammatory gene 
signature as well as more TIL in the TME have been shown to correlate with poorer 
antiproliferative response to aromatase inhibitors in HR+ breast cancer(30). The interplay 
between the TME of HR+/HER2− tumors, estrogen-driven tumor growth, and hormonal 
therapy responsiveness is an important area for further investigation.
Our analysis of tissue-based immune biomarkers in HR+/HER2− breast cancer patients 
treated with neoadjuvant ddAC-T plus bevacizumab (DFCI cohort) showed that sTIL and 
CD8+ cells decrease significantly in post-treatment residual disease relative to pre-treatment 
specimens, with a trend toward decreased post-treatment tPD-L1 expression. Gene 
expression analysis of immune signatures following AC-T with and without bevacizumab 
(DFCI and MD Anderson cohorts) demonstrated no significant change in lymphoid, total T 
cell, or CD8 T cell signatures following chemotherapy, with a significant decrease in T 
regulatory cells. Of note, some differences between tissue-based and expression-based 
analyses (for example, CD8 cells decreased by immunohistochemistry, but did not change 
significantly by NanoString) may be related to the slightly different areas of tissue assessed 
by each method. While NanoString analysis was performed on RNA extracted from circled 
areas of tumor, analysis of immunostaining was performed only on representative captured 
images. Importantly, changes in NanoString signatures post-treatment were highly 
concordant between DFCI and MD Anderson cohorts, suggesting that bevacizumab (a 
component of therapy in DFCI cohort only) was not a major contributor to the observed 
changes.
Given evidence for the immunogenic effects of cytotoxic chemotherapy(6,31), the decrease 
in sTIL and CD8 staining post-chemotherapy was somewhat surprising. However, a similar 
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trend toward decreased TILs following neoadjuvant anthracycline-containing chemotherapy 
has previously been shown in triple-negative breast cancer(32), and in HER2+ breast cancer 
patients treated with neoadjuvant anthracycline-containing chemotherapy with or without 
trastuzumab(33). It is difficult to fully rule out direct hematologic toxicity from 
chemotherapy partially contributing to decreased post-treatment lymphocytes, and it is likely 
that analysis at a single timepoint following completion of neoadjuvant chemotherapy is not 
the optimal way to assess chemotherapy’s effect on the TME. Serial on-treatment biopsies 
over the course of chemotherapy may provide additional information, but in practice are 
difficult to obtain. We posit that cancer cells evolve to become more immunologically silent 
over the course of cancer therapy. This is supported by prior evidence showing that 
metastatic tumors contain lower levels of anti-tumor immune components including TIL, 
CD8 cells, and PD-L1 compared to primary tumors(34), and that response rates to single 
agent checkpoint inhibitors are higher in earlier as opposed to later lines of therapy for 
metastatic breast cancer(35). The mechanisms of post-treatment immune editing are unclear 
and may vary depending on the type of therapy administered, individual breast tumor 
biology, and patient-specific immune factors. Examining biomarkers of antigen presentation 
(for example, HLA-ABC, HLA-DR, and dendritic cell markers), which have been shown to 
account for some immunologic differences between triple-negative and luminal-type breast 
cancers(36), may help to elucidate biology associated with the post-treatment immune-
suppressed TME.
NanoString gene expression analysis of both cohorts showed a significant increase post-
chemotherapy in signatures of the innate immune system and myeloid cell types, including 
functional markers of myeloid inflammation, dendritic cells, and macrophages. While there 
was no significant change in CD68 staining pre- to post-chemotherapy in the DFCI cohort, 
CD68 has been shown to be expressed by other cells besides macrophages(23) and 
furthermore does not distinguish between different macrophage subtypes. An increase in 
myeloid cells following neoadjuvant chemotherapy in breast cancer, including increased 
macrophages, has been shown previously in a small cohort(23), and treatment of breast 
cancer cells with chemotherapy has been shown to increase CSF1, a macrophage 
recruitment factor(37). Macrophages are a broad group of immune cells with highly diverse 
biological roles that are not easily divided in a purely binary fashion, but can function in 
both pro-tumor and anti-tumor capacities. We found that increased expression of genes 
associated with M2-like (pro-tumor) macrophages was predominant post-chemotherapy, 
with particularly large increases in CCL14, CD36, and MRC1, whereas M1-like (anti-tumor) 
macrophage-associated genes changed heterogeneously but were more likely to decrease 
post-chemotherapy. This suggests increased presence and/or activity of M2-like 
macrophages in the chemotherapy-resistant residual tumor cells, which in turn implies a 
possible biological role for M2-like macrophages in chemo-resistance in HR+/HER2− breast 
tumors. Several approaches targeting pro-tumor macrophages and/or immune suppressive 
myeloid precursors have been associated with improved response to immunotherapy and/or 
chemotherapy and are in pre-clinical or clinical development(38–41). Our data, while 
preliminary, would support combined regimens of chemotherapy plus M2 macrophage-
targeting agents in HR+/HER2− breast cancer.
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There are several limitations of our study. First, it is notable that our sample consists 
exclusively of HR+/HER2− breast cancers that were treated with neoadjuvant chemotherapy. 
A large proportion of HR+/HER2− early stage breast cancer patients are treated with 
hormonal therapy alone and are not represented in our study. Second, in our investigation of 
tissue-based immune biomarker changes that occurred following neoadjuvant chemotherapy 
plus bevacizumab in the DFCI cohort, it is difficult to know what effects are attributable to 
chemotherapy, bevacizumab, or both. VEGF, the target of bevacizumab, is a pro-angiogenic 
cytokine that has been shown to mediate an immunosuppressive effect on the TME through 
a range of mechanisms(42). However, side-by-side analysis of NanoString gene expression 
data from the DFCI cohort (who received bevacizumab) and the MD Anderson cohort (who 
did not) demonstrates very high concordance between the two cohorts in expression level 
changes for both individual genes and gene signatures, which is particularly notable given 
that all gene expression assays were performed separately for the two cohorts.
In summary, we have demonstrated that the TME of HR+/HER2− breast tumors differs 
according to tumor biology. Furthermore, our data point to an important role for 
macrophages and, potentially, other myeloid cell types such as dendritic cells and immune-
suppressive myeloid precursors, in response and resistance to chemotherapy for this very 
common breast cancer subtype. Additional studies of tumor-immune interactions and the 
immunologic effects of standard cancer therapies are warranted in a dedicated HR+/HER2− 
breast cancer patient population. Our data support investigating the combination of cytotoxic 
chemotherapy with M2 macrophage-targeting strategies in HR+/HER2− breast cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Financial support:
This work was supported by National Institutes of Health Division of Loan Repayment (AGW and DGS); Susan G. 
Komen Leadership Grant (EPW, CMP); Terri Brodeur Breast Cancer Foundation Grant (DGS); Breast Cancer 
Research Foundation Grant (CMP), Pink Ribbons Project (EAM), and Nancy Owens Memorial Foundation (EAM). 
In addition, we acknowledge the National Institutes of Health (NIH) grant Dana-Farber/Harvard Cancer Center 
Breast Cancer SPORE 5P50CA168504.
Conflict of interest disclosure statement: SMT receives institutional research funding from Genentech, Novartis, 
Pfizer, Eli Lilly, Merck, Nektar, AstraZeneca, Bristol Meyers Squibb, Exelixis, Eisai and has served on advisory 
boards for Genentech, Novartis, Pfizer, Eli Lilly, Merck, Nektar, Eisai, Nanostring, Immunomedics, Bristol Meyers 
Squibb, and AstraZeneca. CMP is an equity stock holder, consultant, and Board of Director Member of 
BioClassifier LLC. CMP is also listed an inventor on patent applications on the Breast PAM50 Subtyping assay. 
EAM serves on advisory boards for Merck, SELLAS Lifesciences, AstraZeneca/MedImmune, TapImmune, and 
Peregrine Pharmaceuticals, and received institutional research funding from Genentech, Astra Zeneca/MedImmune, 
and SELLAS Lifesciences. RW receives grant research funding from Astra Zeneca and Acerta. WTB receives 
research funding from Pfizer. HAB, AS, and PD are employed by NanoString. IK serves as a consultant for Daiichi 
Sankyo and has consulting/contracted research relationships with Genentech/Roche. EPW has received honorarium 
from Genentech, Leap, InfiniteMD, and Lilly. DD has consulted for Axela, Genomic Health Inc, and Novartis, and 
serves on the academic advisory board for Oncology Analytics, Inc. JLG is a consultant for GSK and receives 
sponsored research support from GSK and Eli Lilly.
Waks et al. Page 11














1. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast 
cancer subtypes defined by joint hormone receptor and HER2 status. Journal of the National Cancer 
Institute 2014;106(5) doi 10.1093/jnci/dju055.
2. Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, et al. Prospective 
validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in 
HER2−negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PloS one 
2013;8(12):e79775 doi 10.1371/journal.pone.0079775. [PubMed: 24312450] 
3. Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Droeser RA, et al. Expression of programmed 
death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast cancer 
research and treatment 2014;146(1):15–24 doi 10.1007/s10549-014-2988-5. [PubMed: 24842267] 
4. Vidula N, Yau C, Goga A, Rugo HS. Programmed cell death 1 (PD-1) receptor and prograamed 
death ligand 1 (PD-L1) expression in primary breast cancer (BC); correlations with clinical 
characteristics and patient outcomes. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 2015;33:suppl; abstr 1090.
5. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) 
T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal 
carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8(3):190–8 doi 
10.1593/neo.05733. [PubMed: 16611412] 
6. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic 
chemotherapy: implications for the design of novel and rationale-based combined treatments against 
cancer. Cell death and differentiation 2014;21(1):15–25 doi 10.1038/cdd.2013.67. [PubMed: 
23787994] 
7. Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, et al. Safety and Antitumor Activity 
of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor 
Receptor 2-Negative Advanced Breast Cancer. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2018;24(12):2804–11 doi 
10.1158/1078-0432.Ccr-17-3452. [PubMed: 29559561] 
8. Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. Avelumab, an 
anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b 
JAVELIN Solid Tumor study. Breast cancer research and treatment 2018;167(3):671–86 doi 
10.1007/s10549-017-4537-5. [PubMed: 29063313] 
9. Svensson S, Abrahamsson A, Rodriguez GV, Olsson AK, Jensen L, Cao Y, et al. CCL2 and CCL5 
Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer. Clinical cancer research : an 
official journal of the American Association for Cancer Research 2015;21(16):3794–805 doi 
10.1158/1078-0432.CCR-15-0204. [PubMed: 25901081] 
10. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer cell 
2015;27(4):462–72 doi 10.1016/j.ccell.2015.02.015. [PubMed: 25858805] 
11. Pelekanou V, Villarroel-Espindola F, Schalper KA, Pusztai L, Rimm DL. CD68, CD163, and 
matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts 
survival differently in ER-positive and -negative cancers. Breast cancer research : BCR 
2018;20(1):154 doi 10.1186/s13058-018-1076-x. [PubMed: 30558648] 
12. Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, et al. Role of vascular 
density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast 
cancer patients. Proceedings of the National Academy of Sciences of the United States of America 
2015;112(46):14325–30 doi 10.1073/pnas.1518808112. [PubMed: 26578779] 
13. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual 
breast cancer burden to predict survival after neoadjuvant chemotherapy. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4414–22 doi 
10.1200/JCO.2007.10.6823. [PubMed: 17785706] 
14. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of 
tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs 
Working Group 2014. Annals of oncology : official journal of the European Society for Medical 
Oncology / ESMO 2015;26(2):259–71 doi 10.1093/annonc/mdu450.
Waks et al. Page 12













15. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-
related mRNA profile predicts clinical response to PD-1 blockade. The Journal of clinical 
investigation 2017;127(8):2930–40 doi 10.1172/JCI91190. [PubMed: 28650338] 
16. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature 
2012;490(7418):61–70 doi 10.1038/nature11412. [PubMed: 23000897] 
17. Stover DG, Coloff JL, Barry WT, Brugge JS, Winer EP, Selfors LM. The Role of Proliferation in 
Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based 
Meta-Analysis. Clinical cancer research : an official journal of the American Association for 
Cancer Research 2016;22(24):6039–50 doi 10.1158/1078-0432.Ccr-16-0471. [PubMed: 
27330058] 
18. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised Risk 
Predictor of Breast Cancer Based on Intrinsic Subtypes. Journal of Clinical Oncology 2009;27(8):
1160–7 doi Doi 10.1200/Jco.2008.18.1370. [PubMed: 19204204] 
19. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell 
subsets from tissue expression profiles. Nature methods 2015;12(5):453–7 doi 10.1038/nmeth.
3337. [PubMed: 25822800] 
20. Varet H. 2016 packHV: A few Useful Functions for Statisticians. <https://CRAN.R-project.org/
package=packHV>.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach 
to multiple testing. J R Statist Soc B 1995;57(1):289–300.
22. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-
Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018;379(22):2108–21 doi 
10.1056/NEJMoa1809615. [PubMed: 30345906] 
23. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of 
human breast cancer. Proceedings of the National Academy of Sciences of the United States of 
America 2012;109(8):2796–801 doi 10.1073/pnas.1104303108. [PubMed: 21825174] 
24. Emens LA, Esteva F, Beresford M, Saura C, De Laurentiis M, Kim S-B, et al. Results from 
KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs 
placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC). San Antonio 
Breast Cancer Symposium 2018.
25. Zhao Y, Xia Q, Liu Y, Bai W, Yao Y, Ding J, et al. TCF7L2 and EGR1 synergistic activation of 
transcription of LCN2 via an ERK1/2-dependent pathway in esophageal squamous cell carcinoma 
cells. Cellular signalling 2018;55:8–16 doi 10.1016/j.cellsig.2018.12.007. [PubMed: 30557604] 
26. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 
intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-
treated estrogen receptor-positive breast cancer. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2010;16(21):5222–32 doi 
10.1158/1078-0432.Ccr-10-1282. [PubMed: 20837693] 
27. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating 
lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human 
epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin 
Oncol 2015;33(9):983–91 doi 10.1200/JCO.2014.58.1967. [PubMed: 25534375] 
28. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated 
lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast 
cancer. J Clin Oncol 2010;28(1):105–13 doi 10.1200/JCO.2009.23.7370. [PubMed: 19917869] 
29. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-
infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 
3771 patients treated with neoadjuvant therapy. The Lancet Oncology 2018;19(1):40–50 doi 
10.1016/s1470-2045(17)30904-x. [PubMed: 29233559] 
30. Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, et al. Molecular profiling of 
aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of 
resistance. Clinical cancer research : an official journal of the American Association for Cancer 
Research 2013;19(10):2775–86 doi 10.1158/1078-0432.CCR-12-1000. [PubMed: 23493347] 
Waks et al. Page 13













31. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune 
response: indispensable for therapeutic success? The Journal of clinical investigation 2008;118(6):
1991–2001 doi 10.1172/JCI35180. [PubMed: 18523649] 
32. Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, et al. RAS/MAPK Activation Is 
Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: 
Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical 
cancer research : an official journal of the American Association for Cancer Research 2016;22(6):
1499–509 doi 10.1158/1078-0432.CCR-15-1125. [PubMed: 26515496] 
33. Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, et al. Stromal lymphocyte 
infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and 
lower disease-free survival in HER2−positive breast cancer. Annals of oncology : official journal 
of the European Society for Medical Oncology / ESMO 2017;28(9):2233–40 doi 10.1093/annonc/
mdx309.
34. Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, et al. Immunological 
differences between primary and metastatic breast cancer. Annals of oncology : official journal of 
the European Society for Medical Oncology / ESMO 2018;29(11):2232–9 doi 10.1093/annonc/
mdy399.
35. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term Clinical Outcomes 
and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative 
Breast Cancer: A Phase 1 Study. JAMA oncology 2018 doi 10.1001/jamaoncol.2018.4224.
36. Michea P, Noel F, Zakine E, Czerwinska U, Sirven P, Abouzid O, et al. Adjustment of dendritic 
cells to the breast-cancer microenvironment is subset specific. Nature immunology 2018;19(8):
885–97 doi 10.1038/s41590-018-0145-8. [PubMed: 30013147] 
37. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte 
complexity predicts breast cancer survival and functionally regulates response to chemotherapy. 
Cancer discovery 2011;1(1):54–67 doi 10.1158/2159-8274.Cd-10-0028. [PubMed: 22039576] 
38. Guerriero JL. Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends in 
molecular medicine 2018;24(5):472–89 doi 10.1016/j.molmed.2018.03.006. [PubMed: 29655673] 
39. Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, et al. Entinostat Converts 
Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by 
Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 2018;6(12):1561–77 doi 
10.1158/2326-6066.CIR-18-0070. [PubMed: 30341213] 
40. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers 
resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proceedings of 
the National Academy of Sciences of the United States of America 2014;111(32):11774–9 doi 
10.1073/pnas.1410626111. [PubMed: 25071169] 
41. Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, et al. Entinostat 
Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 
Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clinical cancer research : an 
official journal of the American Association for Cancer Research 2017;23(17):5187–201 doi 
10.1158/1078-0432.CCR-17-0741. [PubMed: 28698201] 
42. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy 
using antiangiogenics: opportunities and challenges. Nature reviews Clinical oncology 2018 doi 
10.1038/nrclinonc.2018.29.
43. Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, et al. Lectin-
type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-
derived suppressor cells in cancer patients. Science immunology 2016;1(2) doi 10.1126/
sciimmunol.aaf8943.
Waks et al. Page 14













Statement of Translational Relevance:
Hormone receptor-positive/HER2−negative (HR+/HER2−) breast cancer is associated 
with low levels of stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1 expression, 
and has shown only marginal responses to single agent checkpoint blockade 
immunotherapy. Further work is needed to better understand the tumor microenvironment 
in HR+/HER2− breast cancer to inform immunotherapy regimens that will bring clinical 
benefit in this common breast cancer subtype. In this study, we analyzed the tumor 
microenvironment before and after neoadjuvant combination chemotherapy in 96 patients 
with HR+/HER2− breast cancer. After chemotherapy, there was a significant decrease in 
sTILs and CD8 T cells, but a significant increase in gene signatures associated with 
myeloid cell types such as macrophages and dendritic cells. Single gene expression 
implicated increased expression of pro-tumor (M2-like) macrophage-specific genes post-
chemotherapy. Our results suggest that regimens combining chemotherapy with 
macrophage-targeting agents should be investigated in HR+/HER2− breast cancer.
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Figure 1. Tissue-based immune biomarkers and tumor intrinsic subtype.
In the DFCI cohort, stromal tumor-infiltrating lymphocytes (TILs; A) were evaluated 
histologically, and CD8+ cells (B), tumor cell PD-L1 expression (tPD-L1; C), and CD68+ 
cells (D) were stained immunohistochemically on full slide sections from treatment-naïve 
breast tumors. The distribution of each biomarker was assessed according to tumor intrinsic 
subtype (Luminal A, Luminal B, or Basal-like) based on the PAM50 gene signature. Each 
boxplot represents the 25th to 75th percentile with the median indicated as the central line 
and whiskers indicating 1.5 × interquartile range.
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Figure 2. Gene-expression based biomarker correlation with chemotherapy response at surgery 
and long-term breast cancer outcomes.
Macrophage signature in the DFCI cohort was calculated using NanoString PanCancer 
Immune (PCI) Panel, and correlation with RCB status was assessed (A). M1-like 
macrophage inferred proportion by CIBERSORT and MDSC signature score(43) was 
calculated from microarray data from our prior meta-analysis of HR+/HER2− tumors treated 
with neoadjuvant chemotherapy(17), and correlation with RCB status was assessed (B-C). 
For A-C, due to a paucity of complete responses, pCR (RCB 0) and RCB-I were grouped 
together. Each boxplot represents the 25th to 75th percentile with the median indicated as the 
central line and whiskers indicating 1.5 × interquartile range. Association of M1-like 
macrophage or CD8 cell proportion by CIBERSORT with distant metastasis-free survival 
was assessed (D-E).
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Figure 3. The tissue-based immune microenvironment before and after chemotherapy (DFCI 
cohort).
Tissue-based immune biomarkers were scored on paired slides from pre- versus post-
preoperative therapy with dose-dense adriamycin/cyclophosphamide plus bevacizumab (A-
D). Histology images (400×) from a patient with pre-to-post-treatment decrease in stromal 
tumor-infiltrating lymphocytes (sTIL), CD8, and CD68 (10% to 5%, 842 cells/mm2 to 206 
cells/mm2, and 414 cells/mm2 to 145 cells/mm2 pre- to post-treatment, respectively) are 
shown. PD-L1 expression on tumor (tPD-L1) and stromal cells was 0% both pre- and post-
treatment for this patient (E).
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Figure 4. NanoString gene expression signatures before and after chemotherapy.
Immune gene expression signatures by PanCancer Immune Profiling Panel (PCI; DFCI 
cohort) or the PanCancer IO 360 Profiling Panel (IO360; MD Anderson cohort) were 
assessed pre- and post-neoadjuvant chemotherapy. Signatures that changed significantly in 
both cohorts are indicated in bold (A). Individual box-and-whisker plots highlight signatures 
of particular interest in both cohorts, with associated statistical test shown for significant 
change and points colored according to RCB status of each individual patient (B). Each 
boxplot represents the 25th to 75th percentile with the median indicated as the central line 
and whiskers indicating 1.5 × interquartile range. Abbreviations: MDACC, MD Anderson 
Cancer Center.
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Figure 5. NanoString individual gene expression before and after chemotherapy.
Individual gene expression by PanCancer Immune Profiling Panel (PCI; DFCI cohort) or the 
PanCancer IO 360 Profiling Panel (IO360; MD Anderson cohort) were assessed pre- and 
post-neoadjuvant chemotherapy. Genes were ranked by fold-change (averaged across both 
cohorts) and the top 10 genes by absolute value of average fold-change, with false discovery 
rate p-value <0.05 in both cohorts, are labeled. Blue dots indicate genes that relate to M2-
like macrophage phenotype; there were no genes in the top 10 that related to M1-like 
macrophage phenotype (A). Individual genes associated with M1-like versus M2-like 
phenotype were hand curated after comprehensive literature search (Table S3) and plotted 
according to log2 fold change (B). Abbreviations: MDACC, MD Anderson Cancer Center.
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Table 1.
Patient/tumor characteristics and surgical outcomes (DFCI and MD Anderson cohorts)
DFCI cohort (N=55) MD Anderson cohort (N=41)
Category Patients: # (%) Category Patients: # (%)
Age (median (IQR)) 47 yrs (39–51 yrs) 57 yrs (46–62 yrs)
HR status ER+/PR+ 45 (82%) ER+/PR+ 32 (78%)
ER+/PR- 9 (16%) ER+/PR- 7 (17%)
ER-/PR+ 1 (2%) ER-/PR+ 0
Unknown 0 Unknown 1 (2%)
Stage at diagnosis
1 2 (4%) 1 1 (2%)
2 41 (75%) 2 24 (59%)
3 12 (22%) 3 14 (34%)
4 0 (0%) 4 1 (2%)
Unknown 0 (0%) Unknown 1 (2%)
Grade 1 3 (6%) 1 2 (5%)
2 30 (55%) 2 22 (54%)
3 22 (40%) 3 12 (29%)
Unknown 0 Unknown 5 (12%)
Intrinsic subtype (assessed in N=38 pts from DFCI cohort) Luminal A 24 (63%)
Luminal B 7 (18%)
Basal 6 (16%) NA NA
Normal 1 (3%)
Not assessed 17
RCB* 0 4 (7%) 0 0
1 5 (9%) 1 3 (7%)
2 22 (40%) 2 22 (54%)
3 23 (42%) 3 16 (39%)
Unable to assess 1 (2%) Unable to assess 0
Characteristics of patients included in two separate cohorts. Stage at diagnosis indicates clinical anatomic stage according to American Joint 
Committee on Cancer Staging, 8th edition.
*
Patients with RCB 0 were excluded from MD Anderson cohort.
Abbreviations: DFCI, Dana-Farber Cancer Institute; IQR, interquartile range; NA, not available/not applicable; RCB, Residual Cancer Burden.
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